What Are Mycoplasma pneumoniae IgG Abs?

Mycoplasma pneumoniae IgG antibodies are proteins your immune system produces in response to infection with Mycoplasma pneumoniae, a common bacterial cause of “walking pneumonia” and bronchitis. A positive IgG result on a blood test generally means you have been exposed to the bacterium at some point, but a single positive reading does not necessarily mean you are sick right now. The distinction between past exposure and active infection is where most of the confusion around this test lives, and understanding how IgG behaves over time is the key to making sense of your results.

The Bacterium Behind the Test

Mycoplasma pneumoniae is an unusual pathogen. Unlike most bacteria, it has no cell wall, which makes it naturally resistant to antibiotics like penicillin that work by attacking cell walls. It infects the conducting airways of the lungs, causing a range of respiratory illness from mild bronchitis to a form of pneumonia often described as “atypical” because it tends to come on gradually and produce a persistent dry cough rather than the dramatic, sudden onset of classic bacterial pneumonia.¹ The organism attaches to airway cells using a specialized structure at one end of its body, which it also uses to glide along the respiratory lining.²

Infections tend to cycle through communities in waves every few years, hitting school-age children and young adults hardest. Most cases resolve on their own or with a course of appropriate antibiotics, but the infection can linger for weeks, which is part of why serological testing (blood tests for antibodies) became a standard diagnostic tool.

How IgG Differs from IgM

When your body first encounters Mycoplasma pneumoniae, it produces IgM antibodies relatively quickly. These typically appear by the end of the first week of symptoms and decline within a few months.³ IgM is often thought of as the “first responder” antibody, and detecting it in a blood sample is generally taken as a sign of recent or current infection.

IgG antibodies show up later. They take longer to ramp up but persist far longer, sometimes for years. Their job is long-term immune memory. This is exactly what makes interpreting a positive IgG result tricky: it could reflect an infection that happened last month, last year, or a decade ago. A single positive IgG test, taken in isolation, tells your doctor you have encountered the bacterium before. It does not, on its own, confirm that your current cough is caused by Mycoplasma pneumoniae.

Making Sense of a Positive IgG Result

Because IgG lingers, doctors rely on a few strategies to distinguish old exposure from active infection. The most reliable approach is paired blood samples, sometimes called acute and convalescent sera. A blood draw is taken early in the illness (the acute sample) and a second one is taken roughly one to two weeks later (the convalescent sample). If the IgG level rises substantially between the two draws, that rising titer is strong evidence of a current infection. A significant increase in IgG titers, seroconversion from negative to positive, or the presence of IgM antibodies are all considered sufficient evidence of an active Mycoplasma pneumoniae infection.⁴

One study examining adult patients with Mycoplasma pneumoniae pneumonia found that for paired serum samples taken within seven days, an IgG concentration change of roughly 1.5-fold or more, combined with a threshold IgG level by day seven, served as useful diagnostic criteria.⁵ The classic textbook standard is a fourfold rise in titer between paired samples, though newer quantitative methods have refined this somewhat.

In practice, waiting for a second blood draw is not always practical. A patient with a cough and a fever does not always return two weeks later for another needle stick. This is why many clinicians order IgM alongside IgG, or supplement serology with molecular testing like PCR, which detects the bacterium’s genetic material directly from a throat or nasal swab. PCR tends to perform better in the first week of illness, while serology becomes more informative as the immune response develops.⁴ The two approaches complement each other nicely, covering different time windows of the infection.

How the Test Is Actually Run

Most Mycoplasma pneumoniae IgG tests use one of two laboratory methods: ELISA (enzyme-linked immunosorbent assay) or CLIA (chemiluminescence immunoassay). Both work by exposing your blood sample to Mycoplasma pneumoniae proteins and measuring whether your IgG antibodies bind to them. ELISA has been the workhorse method for decades, while CLIA is a newer, often automated alternative that has become common in larger hospital labs.

When researchers have compared the two methods head-to-head, they perform similarly. One comparison found that the overall consistency between CLIA and ELISA for IgG results was above 88%, with strong agreement between the methods.⁶ Another study found that a newer automated CLIA system produced results equivalent to quantitative ELISA when analyzing paired acute and convalescent samples.⁷ From a patient’s perspective, the method used matters less than how the result is interpreted. Both can give you a quantitative number (how much IgG is present) rather than just a positive or negative, which is what allows doctors to track changes over time.

A broader evaluation of 12 commercial serological tests found meaningful variation in how well different assay kits performed, particularly for IgM detection. Some kits had low specificity, meaning they flagged too many false positives.⁸ IgG assays generally performed more consistently across platforms than IgM assays, but discrepancies between different commercial IgG tests have also been observed, and the lack of a universally accepted gold standard makes it hard to declare any single kit the definitive winner.

How Common Is a Positive IgG Result

Given how widespread Mycoplasma pneumoniae is, a surprisingly large portion of the population carries IgG antibodies against it without being sick at all. These are simply markers of past encounters with the bacterium.

A large Finnish seroprevalence study found that IgG positivity starts climbing early in childhood, reaching about 16% in two- to four-year-olds, continues rising through adolescence, and levels off at roughly 40 to 50% in adults. Among people over 65, the prevalence reached as high as 60%.⁹ A more recent study in Chinese children aged zero to six found a similar age-dependent pattern: IgG positivity rose from about 10% in infants to roughly a third of six-year-olds, with age being the only significant predictor (gender made no difference).¹⁰

This matters for interpretation. If you are a healthy adult with a positive Mycoplasma pneumoniae IgG, there is roughly a coin-flip chance that result simply reflects an infection you had years ago. A positive IgG by itself, without either a rising titer, a positive IgM, or a positive PCR, is not diagnostic of anything current. If your doctor ordered the test because you have respiratory symptoms, they will almost certainly be looking at the full picture rather than relying on IgG alone.

Where IgG Testing Gets Unreliable

No serological test is perfect, and Mycoplasma pneumoniae serology has some well-known weak spots. One of the most significant is cross-reactivity. Your immune system can sometimes produce antibodies that bind to Mycoplasma pneumoniae proteins even when the real culprit is a different infection. An evaluation of multiple commercial assays found that cross-reactivity was particularly problematic in patients with acute Epstein-Barr virus or cytomegalovirus infections, where some kits produced false-positive IgM results. IgG discrepancies between different test kits were also observed, and because there is no universally accepted gold standard for Mycoplasma pneumoniae serology, some ambiguous results are difficult to resolve definitively.

Children present an additional interpretive challenge. In school-age children hospitalized with Mycoplasma pneumoniae pneumonia, the initial IgM positivity rate on admission was only about 64%, climbing to roughly 98% by one week after admission. IgA antibodies, which some researchers have proposed as an alternative marker, started even lower and never reached the same sensitivity.¹¹ For children experiencing their very first Mycoplasma pneumoniae infection, both IgM and IgG may be absent early in the illness because the immune system has not yet had time to mount a detectable response. Testing too early can miss the infection entirely.

On the other end of the spectrum, IgM can sometimes linger longer than expected after an initial infection, persisting for several months or more.³ This means a positive IgM result does not always mean “right now.” Similarly, in a reinfection (someone catching Mycoplasma pneumoniae for a second or third time), the IgM response may be blunted or absent while IgG rises quickly, because the immune system’s memory kicks in and skips the IgM step. In those cases, a rising IgG titer may be the only serological clue.

Why Accurate Diagnosis Matters

Part of the reason clinicians put effort into sorting out Mycoplasma pneumoniae infection is that treatment decisions depend on it. Because the bacterium lacks a cell wall, the penicillin-class and cephalosporin antibiotics commonly prescribed for other types of pneumonia are useless against it. Accurate laboratory diagnosis helps guide the choice toward antibiotics that actually work, reducing unnecessary prescriptions and slowing the development of antibiotic resistance.¹¹

In mild cases, walking pneumonia often resolves without targeted treatment. But for more severe infections, particularly in younger children or people with weakened immune systems, starting the right antibiotic promptly can shorten illness and reduce the risk of complications. The IgG test is one piece of the diagnostic puzzle. Used alone, it is weak. Combined with IgM, paired titers, PCR, and the clinical picture, it becomes genuinely useful.

Asymptomatic Carriage and Transmission

One question that sometimes comes up is whether you can carry Mycoplasma pneumoniae without symptoms and still test positive. Research during community outbreaks has found that asymptomatic carriage is actually uncommon. During one school-based investigation, only about 0.4% of children were positive by PCR, and that child had respiratory symptoms.¹² So while IgG positivity is extremely common in the general population (reflecting past infections), actively carrying the organism without being sick is not.

Mycoplasma pneumoniae spreads through respiratory droplets, and outbreaks tend to roll through schools, military barracks, and households. Transmission modeling has been used to estimate the rate at which susceptible people become infected and how long immunity lasts after infection, with mathematical models fitted to age-specific IgG seroprevalence data to estimate these parameters.¹³ The fact that seroprevalence keeps climbing with age suggests immunity is not permanent; reinfection happens, which is consistent with the observation that IgG levels can wane and then get boosted by a new encounter with the bacterium.

Cold Agglutinins and the Immune Response

Mycoplasma pneumoniae infection sometimes triggers a peculiar immune side effect that goes beyond the usual IgM and IgG story. Some patients develop cold agglutinins, antibodies that bind to red blood cells at low temperatures. These antibodies are directed against a carbohydrate called the I antigen, which sits on the surface of red blood cells and also happens to be present on the respiratory cells where Mycoplasma pneumoniae attaches.¹⁴

The leading explanation is that the bacterium’s interaction with the I antigen on airway cells essentially tricks the immune system into producing antibodies that also recognize the same molecule on red blood cells. In cooler parts of the body, like the fingers and toes, these antibodies bind to red blood cells and can trigger their destruction, a process called hemolysis. In most cases the effect is mild and self-limiting, but rare severe cases have led to significant anemia and organ complications. Early research in animal models confirmed that injecting live or killed Mycoplasma pneumoniae could produce cold agglutinins with specificity for the I antigen, and that the strength of this response varied with genetic background.¹⁵

Cold agglutinins typically appear by the end of the first week of fever and disappear within two to three months.³ They are not specific enough to be used as a standalone diagnostic test for Mycoplasma pneumoniae, but their presence in a patient with atypical pneumonia is a useful clue. If you have had a blood draw during a Mycoplasma infection and the lab noted cold agglutinins, that is this mechanism at work.

Vaccine Research and the Future of IgG Testing

No approved vaccine against Mycoplasma pneumoniae currently exists for humans, but research is active. Animal studies have shown that vaccination can produce robust IgG and IgM responses alongside mucosal IgA in the airways. In one murine model, mice that received a live oral vaccine developed strong recall responses when later exposed to the bacterium, with systemic IgG and IgM rising alongside lung-specific IgA and expansion of multiple immune cell types.¹⁶

If a vaccine eventually reaches the clinic, IgG testing would take on a slightly different meaning. In a vaccinated population, a positive IgG might reflect vaccination rather than natural infection, similar to what happened with hepatitis B testing after widespread vaccination. Distinguishing vaccine-induced IgG from infection-induced IgG would likely require looking at which specific proteins the antibodies target, since vaccines often use only a subset of the bacterium’s proteins. That is a bridge to cross when the time comes, but it is worth knowing that the meaning of a positive IgG result is always shaped by context, and that context may shift as prevention strategies evolve.